The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Timothy Caulfield

Health Law and Science Policy Group

University of Alberta




Name/email consistency: medium



  • Health Law and Science Policy Group, University of Alberta, Edmonton, Canada. 1999 - 2011
  • Faculty of Law, University of Alberta, Edmonton. 2002 - 2007
  • Stanford University Program in Genomics, Ethics, and Society, Palo Alto, USA. 1999


  1. Supported by science?: what canadian naturopaths advertise to the public. Caulfield, T., Rachul, C. Allergy. Asthma. Clin. Immunol (2011) [Pubmed]
  2. Direct-to-consumer genetic testing: good, bad or benign?. Caulfield, T., Ries, N.M., Ray, P.N., Shuman, C., Wilson, B. Clin. Genet. (2010) [Pubmed]
  3. Stem cell research policy and iPS cells. Caulfield, T., Scott, C., Hyun, I., Lovell-Badge, R., Kato, K., Zarzeczny, A. Nat. Methods (2010) [Pubmed]
  4. The stem cell research environment: a patchwork of patchworks. Caulfield, T., Zarzeczny, A., McCormick, J., Bubela, T., Critchley, C., Einsiedel, E., Galipeau, J., Harmon, S., Huynh, M., Hyun, I., Illes, J., Isasi, R., Joly, Y., Laurie, G., Lomax, G., Longstaff, H., McDonald, M., Murdoch, C., Ogbogu, U., Owen-Smith, J., Pattinson, S., Premji, S., von Tigerstrom, B., Winickoff, D.E. Stem. Cell. Rev (2009) [Pubmed]
  5. Direct-to-consumer genetics and health policy: a worst-case scenario?. Caulfield, T. Am. J. Bioeth (2009) [Pubmed]
  6. Research ethics recommendations for whole-genome research: consensus statement. Caulfield, T., McGuire, A.L., Cho, M., Buchanan, J.A., Burgess, M.M., Danilczyk, U., Diaz, C.M., Fryer-Edwards, K., Green, S.K., Hodosh, M.A., Juengst, E.T., Kaye, J., Kedes, L., Knoppers, B.M., Lemmens, T., Meslin, E.M., Murphy, J., Nussbaum, R.L., Otlowski, M., Pullman, D., Ray, P.N., Sugarman, J., Timmons, M. PLoS Biol. (2008) [Pubmed]
  7. Patents, commercialization and the Canadian stem cell research community. Caulfield, T., Ogbogu, U., Murdoch, C., Einsiedel, E. Regenerative. Medicine (2008) [Pubmed]
  8. Biomedical research and the commercialization agenda: a review of main considerations for neuroscience. Caulfield, T., Ogbogu, U. Account. Res (2008) [Pubmed]
  9. Why a criminal ban? Analyzing the arguments against somatic cell nuclear transfer in the Canadian parliamentary debate. Caulfield, T., Bubela, T. Am. J. Bioeth (2007) [Pubmed]
  10. Obesity, legal duties, and the family physician. Caulfield, T. Can. Fam. Physician (2007) [Pubmed]
  11. Myriad and the mass media: the covering of a gene patent controversy. Caulfield, T., Bubela, T., Murdoch, C.J. Genet. Med. (2007) [Pubmed]
  12. Human dignity: a guide to policy making in the biotechnology era?. Caulfield, T., Brownsword, R. Nat. Rev. Genet. (2006) [Pubmed]
  13. Gene patents, health care policy and licensing schemes. Caulfield, T., von Tigerstrom, B. Trends Biotechnol. (2006) [Pubmed]
  14. Evidence and anecdotes: an analysis of human gene patenting controversies. Caulfield, T., Cook-Deegan, R.M., Kieff, F.S., Walsh, J.P. Nat. Biotechnol. (2006) [Pubmed]
  15. Introduction: genetic diversity and science communication. Caulfield, T. Clin. Genet. (2006) [Pubmed]
  16. Trust, patents and public perceptions: the governance of controversial biotechnology research. Caulfield, T., Einsiedel, E., Merz, J.F., Nicol, D. Nat. Biotechnol. (2006) [Pubmed]
  17. A systematic review of how homeopathy is represented in conventional and CAM peer reviewed journals. Caulfield, T., DeBow, S. BMC. Complement. Altern. Med (2005) [Pubmed]
  18. Human dignity as a criterion for science policy. Caulfield, T., Chapman, A. PLoS Med. (2005) [Pubmed]
  19. Policy conflicts: gene patents and health care in Canada. Caulfield, T. Community. Genet (2005) [Pubmed]
  20. Biotechnology and the popular press: hype and the selling of science. Caulfield, T. Trends Biotechnol. (2004) [Pubmed]
  21. Scientific freedom and research cloning: can a ban be justified?. Caulfield, T. Lancet (2004) [Pubmed]
  22. Law and policy in the era of reproductive genetics. Caulfield, T., Knowles, L., Meslin, E.M. J. Med. Ethics (2004) [Pubmed]
  23. Variations and voids: the regulation of human cloning around the world. Pattinson, S.D., Caulfield, T. BMC. Med. Ethics (2004) [Pubmed]
  24. The commercialisation of medical and scientific reporting. Caulfield, T. PLoS Med. (2004) [Pubmed]
  25. Genetic technologies, health care policy and the patent bargain. Caulfield, T.A., Knoppers, B.M., Gold, E.R., Sheremeta, L.E., Bridge, P.J. Clin. Genet. (2003) [Pubmed]
  26. Human cloning laws, human dignity and the poverty of the policy making dialogue. Caulfield, T. BMC. Med. Ethics (2003) [Pubmed]
  27. Physicians' liability and drug formulary restrictions. Caulfield, T., Siminoski, K. CMAJ (2002) [Pubmed]
  28. Creating needs? A review of survey data and concerns relevant to the commercialization of genetic testing. Caulfield, T., Wertz, D. Community. Genet (2001) [Pubmed]
  29. Patenting human genetic material: refocusing the debate. Caulfield, T., Gold, E.R., Cho, M.K. Nat. Rev. Genet. (2000) [Pubmed]
  30. Regulating the genetic revolution. Caulfield, T., Hirtle, M. Mol. Med. Today (1999) [Pubmed]
  31. The law, adolescents, and the APOE epsilon 4 genotype: a view from Canada. Caulfield, T.A. Genet. Test. (1999) [Pubmed]
WikiGenes - Universities